Treat-to-target tested in psoriatic arthritis

Treating to target for psoriatic arthritis gives a better ARC20 response than standard care, a UK trial shows.

Patients with early untreated psoriatic arthritis are nearly twice as likely to achieve an ARC20 response after 48 weeks of treatment to a target of ‘minimal disease activity’ compared with normal care, the randomised controlled trial of 206 patients suggests.